Immunovant Sciences GmbH

The Myasthenia Gravis Treatment Market is set to grow significantly by 2034, driven by improved diagnostics, emerging therapies, and increased awareness. Key companies like Horizon Therapeutics and Amgen are developing novel treatments. The market size reached USD 4,950 million in 2023, with the U.S. seeing 129 thousand cases.

The 'Graves' Disease - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides a comprehensive overview of the current pipeline landscape for Graves' Disease treatments, including detailed descriptions of drugs like Batoclimab, VRDN-001, and Linsitinib, which are in various stages of clinical development. The report highlights key companies such as Viridian Therapeutics, Immunovant Sciences, and Sling Therapeutics, and covers therapeutic assessments, pipeline development activities, and emerging trends in drug development for Graves' Disease.